Laboratory and clinical characteristics of MPL mutant patients compared with MPL wild-type patients who were categorized according to their JAK2V617F mutational status
| . | MPL, mutant (A) . | MPL wild-type . | P . | |||
|---|---|---|---|---|---|---|
| JAK2, wild-type (B) . | JAK2V617F, mutant (C) . | (A) vs (B) . | (A) vs (C) . | (B) vs (C) . | ||
| Number of patients | 30 | 418 | 546 | — | — | — |
| Male, no (%) | 9 (30%) | 144 (34%) | 170 (31%) | .7 | .9 | .3 |
| Median age, y (range) | 56 (22-84) | 50 (8-87) | 56 (15-97) | .006 | .33 | <.001 |
| MPL mutant allele burden, %* | 39 ± 27 | — | — | — | — | — |
| JAK2V617F allele burden, %* | 11 ± 8† | — | 25 ± 13 | — | .002 | — |
| White blood cell count, ×109/L* | 8.8 ± 3.1 | 8.5 ± 2.1 | 9.5 ± 3.1 | .8 | .2 | <.001 |
| Hemoglobin, g/L* | 134 ± 13 | 135 ± 22 | 142 ± 21 | .7 | <.001 | <.001 |
| Platelet count, ×109/L* | 956 ± 331 | 935 ± 315 | 791 ± 211 | .8 | .004 | <.001 |
| LDH, U/L* | 459 ± 182 | 336 ± 128 | 338 ± 116 | .03 | .005 | .1 |
| Serum ferritin, μg/L* | 110 ± 82 | 82 ± 85 | 93 ± 96 | .08 | .1 | .7 |
| Splenomegaly, no (%; n = 892)‡ | 5 (17%) | 71 (20%) | 107 (21%) | .9 | .9 | .8 |
| Pruritus, no (%; n = 663)‡ | 4 (13%) | 13 (5%) | 34 (10%) | .1 | .5 | .2 |
| Arterial events at diagnosis, no (%) | 3 (10%) | 24 (6%) | 66 (12%) | .4 | .9 | .008 |
| Arterial events at follow-up, no (%) | 4 (13%) | 6 (1%) | 20 (4%) | .002 | .05 | .04 |
| Venous events at diagnosis, no (%) | 1 (3%) | 10 (2%) | 29 (5%) | .5 | .9 | .09 |
| Venous events at follow-up, no (%) | 2 (7%) | 5 (1%) | 12 (2%) | .07 | .1 | .3 |
| Microvessel disturbances, no (%) | 18 (60%) | 106 (25%) | 170 (31%) | <.001 | .001 | .1 |
| Major hemorrhage, no (%)§ | 2 (7%) | 15 (4%) | 20 (4%) | .1 | .1 | .8 |
| . | MPL, mutant (A) . | MPL wild-type . | P . | |||
|---|---|---|---|---|---|---|
| JAK2, wild-type (B) . | JAK2V617F, mutant (C) . | (A) vs (B) . | (A) vs (C) . | (B) vs (C) . | ||
| Number of patients | 30 | 418 | 546 | — | — | — |
| Male, no (%) | 9 (30%) | 144 (34%) | 170 (31%) | .7 | .9 | .3 |
| Median age, y (range) | 56 (22-84) | 50 (8-87) | 56 (15-97) | .006 | .33 | <.001 |
| MPL mutant allele burden, %* | 39 ± 27 | — | — | — | — | — |
| JAK2V617F allele burden, %* | 11 ± 8† | — | 25 ± 13 | — | .002 | — |
| White blood cell count, ×109/L* | 8.8 ± 3.1 | 8.5 ± 2.1 | 9.5 ± 3.1 | .8 | .2 | <.001 |
| Hemoglobin, g/L* | 134 ± 13 | 135 ± 22 | 142 ± 21 | .7 | <.001 | <.001 |
| Platelet count, ×109/L* | 956 ± 331 | 935 ± 315 | 791 ± 211 | .8 | .004 | <.001 |
| LDH, U/L* | 459 ± 182 | 336 ± 128 | 338 ± 116 | .03 | .005 | .1 |
| Serum ferritin, μg/L* | 110 ± 82 | 82 ± 85 | 93 ± 96 | .08 | .1 | .7 |
| Splenomegaly, no (%; n = 892)‡ | 5 (17%) | 71 (20%) | 107 (21%) | .9 | .9 | .8 |
| Pruritus, no (%; n = 663)‡ | 4 (13%) | 13 (5%) | 34 (10%) | .1 | .5 | .2 |
| Arterial events at diagnosis, no (%) | 3 (10%) | 24 (6%) | 66 (12%) | .4 | .9 | .008 |
| Arterial events at follow-up, no (%) | 4 (13%) | 6 (1%) | 20 (4%) | .002 | .05 | .04 |
| Venous events at diagnosis, no (%) | 1 (3%) | 10 (2%) | 29 (5%) | .5 | .9 | .09 |
| Venous events at follow-up, no (%) | 2 (7%) | 5 (1%) | 12 (2%) | .07 | .1 | .3 |
| Microvessel disturbances, no (%) | 18 (60%) | 106 (25%) | 170 (31%) | <.001 | .001 | .1 |
| Major hemorrhage, no (%)§ | 2 (7%) | 15 (4%) | 20 (4%) | .1 | .1 | .8 |
Unless otherwise specified, all data were collected at diagnosis. P values in bold indicate statistically significant differences (P < .05).
Mean value (± SD) is reported.
Refers only to the 8 patients who harbored both JAK2V617F and MPLW515L/K mutation.
Numbers within parentheses indicate the number of patients for whom information was available.
Includes patients with hemorrhage either at diagnosis, during follow-up, or both.